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Abstract
The presence of cancer stem cells (CSCs) in colorectal cancer (CRC) has been associated
with tumor initiation, metastasis, relapse, and resistance to chemotherapy and radio‐
therapy. Therefore, a better knowledge of the molecular mechanisms involved in the
regulation of CSCs is required to develop treatments that are more effective. Like normal
cells, cancer cells contain molecular clocks that generate circadian rhythms in gene
expression and metabolic activity. Disruption of circadian rhythms has been linked to
increased cancer risk, chemoresistance, and progression in CRC. CSCs also generate
rhythms, which could be exploited with a chronopharmacological approach. Although
the regulation of the expression of circadian rhythm genes appears to be mediated mainly
by transcription–translation feedback loops, the existence of forms of nontranscription‐
al regulation has been demonstrated. Particularly, microRNAs (miRNA) and SIRT1 are
significant  players  in  regulating  various  aspects  of  the  circadian  clock  function.
Furthermore, miRNA acts as a regulator of cancer progression by regulating the CSC
characteristics through SIRT1. These findings led us to hypothesize that there is a circadian
rhythm of CSC markers regulated by miRNAs in CRC with SIRT1 acting as a mediator of
miRNA activity. The pharmacological regulation of SIRT1, and therefore of the circadian
machinery, could result in antiproliferative effects and increased sensitivity to antitu‐
mor treatments in CRC.
Keywords: circadian rhythms, cancer stem cells, SIRT1, redox homeostasis, melatonin
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Cancer is a major health burden and one of the leading causes of death worldwide. There are
more than 200 known types of cancer, being CRC one of the most common cancers. In men, CRC
is the third most common, after lung and prostate cancer. In women, CRC is the second most
common cancer behind breast cancer [1].
Cancer begins with the transformation of a normal cell into a tumor cell through a multistage
process. In this process, the changes are the result of the interaction between the genetic factors
of the patient and external agents, including physical, chemical, or biological agents. Aging is
another fundamental factor in the development of cancer. The coming years will see an increase
in the total number of cancer cases [2]. This will be caused by the dramatic increase in average
life expectancy during the last century in the industrialized world and by the fact that about
5% of the population in the developed countries is predicted to have more than 85 years by
2050 [3].
CRC is an excellent example of the increased cell malignancy with age; according to the Centers
for Control and Prevention of Diseases, the incidence rate of CRC increases progressively with
age. In 2007, the Surveillance, Epidemiology, and End Results Program registry reported that
CRC incidence was 74.5/100,000 in persons aged 50–64 years, 186.0/100,000 in persons aged
65–74 years, and 290.1/100,000 in persons aged ≥75 years [4].
Little is known about the precise biochemical mechanisms responsible for the rise in CRC rates
with aging. Some authors have proposed cancer stem cells/stem-like cells (CSCs/CSLCs) as the
main factor associated with age-related rise in CRCs [5]. CSCs are a small subpopulation of
cells that might play a critical role in CRC progression and resistance to chemotherapy and
radiotherapy. Because of these resistances, CSCs play an important role in the processes of
tumor recurrence and metastasis [6–8]. Therefore, it is increasingly likely that therapies that
specifically target CSCs will be needed for the complete eradication of the tumor [7] because
these cells are responsible for the morbidity and mortality associated with this type of cancer
[9].
2. CSCs and CRC
CSCs, also known as tumor-initiating cells, were first identified by John Dick in acute myeloid
leukemia in the late 1990s. Since then, they have been an intense focus of cancer research. CSCs
have recently been identified in several solid tumors, including breast [10], colon [11], head
and neck [12], lung [13], pancreas [14], and central nervous system cancer [15]. CSCs are
defined as cancer cells that possess characteristics associated with normal stem cells, specifi‐
cally the ability to self-renew and differentiate into multiple cell types, in particular into all the
heterogeneous cell types found in a particular cancer sample [16] (Figure 1).
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Figure 1. The cancer stem cells (CSCs) theory suggests that tumors grow like normal tissues of the body. In this way,
the CSCs are able to both self-renew extensively, copying to them, and to produce the tissue grow (cancer tissue). In
this process, the CSCs produce transit amplifying cells that have the capacity to divide a certain number of times, and
then, they can differentiate into specialized heterogeneous tumor cells that do not have the skill to divide and therefore
do not contribute to tumor growth.
Little is known about the origin of CSCs. Several proposals have been made regarding the
origin of CSCs and probably several answers are possible depending on the tumor type and
the tumor phenotype. In brief, CSC can arise if there are mutations in a developing stem or
progenitor cells, in adult stem cells or adult progenitor cells, or in differentiated cells that
acquire stem-like attributes [17]. Some data pointed to adult stem cells as origin of CSC in CRC.
In this way, according to the most accepted model of CRC progression [18], four to five
mutations in tumor suppressor genes or oncogenes are required and this takes about 8–12
years. As the colonic mucosa is a highly dynamic tissue, the mucosal cells are constantly
replaced with cells derived from crypt stem cells. Therefore, only the long-lived cells (stem
cells) may serve as reservoirs for accumulation of such mutations and epigenetic modifications.
In CRC, the presence of CSC has been correlated to tumor initiation, progression, metastasis,
relapse, and resistance to chemotherapy and radiotherapy. [19]. CSCs have been isolated from
CRC and are identified by the expression of specific surface markers and by their functional
characteristics: CD44, CD166, CD133, ALDH1 (aldehyde dehydrogenase isoform 1), and ESA
(epithelial-specific antigen, also known as EpCAM) [20]. Moreover, CSCs have been involved
in the transition from adenoma to carcinoma, and this issue is age-dependent. In addition, an
age-related rise in CSC has been observed in normal colonic mucosa and in premalignant
adenomatous polyps. Moreover, the CSCs found showed an increased expression of CD44,
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CD166, ALDH1, miR-21, and oncogenic miRNA, which suggests a predisposition of the organ
to developing colorectal cancer [21]. Another characteristic of CSCs is that they can undergo
epithelial–mesenchymal transition [22]. The fact that CSCs are resistant to conventional
therapies has important implications in the development of novel strategies, such as CSCs-
targeted treatments. It makes sense that eradication of CSCs or, alternatively, the attenuation
of their malignant and stemness properties can lead us to achieve more effective therapeutic
approaches. Therefore, development of specific CSCs-targeted therapies holds hope for
improvement in the survival and quality of life of cancer patients, especially in patients with
metastatic disease.
3. Epigenetic phenomena associated with CRC: miRNA regulatory
network
Epigenetic processes are potentially reversible genetic modifications that lead to genomic
instability and malfunction but that do not involve changes in DNA sequence. Epigenetic
changes include (a) altered DNA methylation, (b) chromatin remodeling, and (c) small non-
coding RNA (miRNAs). Notable changes in epigenetics have been reported for several age-
related diseases, including CRC [23]. miRNAs are a small non-coding RNAs with 18–25
nucleotides found in plants, animals, and some viruses that are involved in RNA silencing and
regulation of gene expression at the post-transcriptional level. miRNAs bind to the 3′-
untranslated region (3′-UTR) of the protein-coding messenger RNAs (mRNAs). A single
miRNA may regulate multiple mRNA targets and these small molecules are predicted to
regulate approximately 60% of the human genes [24].
miRNAs are involved in different biological processes, including embryogenesis and the
maintenance of stem cell characteristics, cell proliferation, metabolism, and transduction
signals as in resistance to cancer treatments, including chemo- and radiotherapy [25, 26]. The
presence of certain miRNAs has been associated with tumor development, tumor cell invasion,
and cancer metastasis, and they may be of value as biomarkers for tumor detection and
prognosis [27]. In addition, evidences show that miRNAs participate as oncogenic or tumor
suppressors in the developmental and physiological processes of several human cancers,
including CRC.
3.1. miRNA regulatory network in CRC
Approximately 450 unique miRNAs have been associated with CRC. In this disease, the
aberrant expression of miRNAs has been associated with initiation and progression of CRC.
Of special interest is miRNA involvement in the invasion, migration, and progression of
disease through epithelial–mesenchymal transition into metastases. This event occurred due
to IL6/STAT3 mediation and/or TP53 inactivation [28]. miRNAs are also involved in resistance
to radio-chemotherapy [29].
Furthermore, miRNAs might regulate cell proliferation and apoptosis by targeting mitogen
receptor tyrosine kinases and cell cycle regulators, such as cyclin-dependent kinases
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(CDKs), reciprocal miRNA interactions with MYC (v-myc avian myelocytomatosis viral on‐
cogene homolog) and TP53, and by regulating the proapoptotic and antiapoptotic mRNAs
[30].
Moreover, due to the altered expression of miRNAs in tumor development, they have been
proposed as tissue and circulation biomarkers (blood derivates and feces). They might play a
role in the prognostic and predictive diagnosis of CRC [31]. Table 1 shows the potential roles
of miRNA in CRC. Additionally, miRNA-related polymorphisms might disrupt their binding
sites, miRNA processing, and expression. In this way, the single-nucleotide polymorphism
(SNP) and other genetic abnormalities might be of utility in the study of the risk and prognosis
of CRC.
Role in CRC miRNA
Oncogene Proliferation miR-21, miR-92a, miR-96, miR-135a, miR-135b
Apoptosis miR-21







Tumor suppressor Proliferation let-7, miR-7, miR-18a, miR-26b, miR-27b, miR-143,
miR-144, miR-145, miR-194, miR-320a
Apoptosis miR-26b, miR-34a, miR-194, miR-195, miR-365, miR-491
Angiogenesis miR-27b, miR-145, miR-101, miR-126
Invasion miR-26b, miR-145, miR-194
Migration miR-26b, miR-145, miR-194
Circulatory biomarkers Diagnosis miR-21, miR-31, miR-34a, miR-92a, miR-143, miR-145, miR-601,
miR-760
Prognosis/survival miR-21, miR-124-5p, miR-141, miR-155, miR-182, miR-200c
Chemotherapy miR-17-5p, miR-19a, miR-20a, miR-27b, miR-126,
miR-130, miR-140, miR-145, miR-192, miR-216, miR-200c
Table 1. MiRNAs described in CRC
MiRNA has also been described with high potential as therapeutic target. According to
Schetter et al., the two strategies for miRNA-based therapies are (a) to inhibit oncogenic
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miRNAs and (b) to restore tumor suppressor miRNAs. Some preclinical models have shown
that both strategies might be effective in the treatment of CRC cancers [29].
3.2. miRNA regulation of CSC in CRC
Many studies have reported that miRNAs are key players in the regulation of CSCs [32]. Bitarte
et al. [33] have described that miR-451 is involved in the self-renewal, tumorigenicity, and
chemoresistance of CRC stem cells. Up-regulation of miR-451 resulted in reduction of colon
sphere formation and growth, inhibition of tumorigenicity in vivo, and sensitization to the
active metabolite of irinotecan, SN38. This metabolite might be related to miR-451–mediated
down-regulation of cyclooxygenase-2 (COX-2) and WNT (Wingless-type MMTV integration
site family) pathway, essential to maintain cell stemness. On the other hand, Bitarte et al. also
described that the regulation of expression of ATP-binding cassette (ABCB1) by miR-451 could
decrease SN38 resistance.
Moreover, it has been suggested that miR-215 and miR-140 could control the slow proliferation
and the chemoresistance of CSCs in the colon. In this respect, Jones et al. [34] described
miRNA-215 (miR-215) as a direct transcriptional target of CDX1 in CRC stem cell differentia‐
tion. Song et al. [35] suggested miR-215 as molecular modulator of chemoresistance in CSC in
CRC. Moreover, Yu et al. [36] have reported that miR-93 suppresses proliferation and colony
formation of human CRC stem cells.
4. Circadian rhythms and CSC in CRC
Circadian rhythms are daily rhythms that take the form of a sine wave with high or active and
low or quiet periods over the 24-hour clock. Many biological processes are temporally
coordinated so that groups of genes called “clock genes” and their products are expressed at
different critical times of the day, being likewise coordinated in circadian time [37]. A master
clock in the suprachiasmatic nucleus (SCN) of the hypothalamus organizes the circadian
system in a hierarchical manner. The SCN receives photic input through direct retinal
innervation that initiates gene expression in the SCN [38]. In this way, light exposure syn‐
chronizes the SCN clock to solar time, adapting the oscillator to exact 24-hour cycle. The master
clock of the SCN communicates day-night information to the rest of the body. The SCN receives
light input from the retina and then conveys the photic information into neural or humoral
signals. This information is then sent to peripheral circadian clocks that exist in almost all cells
of the body and synchronize them to the same phase [39]. Whereas light is the dominant
rhythmic signal for the SCN oscillator, the peripheral clocks respond to other environmental
signal, such as body temperature, hunger, and hormone secretion cycles, and modify their
phase accordingly [40, 41].
4.1. Regulation of circadian rhythms in mammals
In mammals, these daily rhythms are maintained by autoregulatory transcriptional and
translational feedback and feed-forward loops (TTFLs) [42]. The core clock genes are BMAL1
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(brain and muscle aryl-hydrocarbon receptor nuclear translocator-like 1), CLOCK (circadian
locomotor output cycles kaput), PER (period homolog), and CRY (cryptochrome) [41]. BMAL1
heterodimerizes with either CLOCK or NPAS2 (neuronal PAS domain protein 2) and binds to
E-box elements in PER (PER1-3) and CRY (CRY1-2) promoter regions and activates their
transcription. Upon accumulation in the cytoplasm, PER and CRY proteins translocate to the
nucleus where they repress the BMAL1: CLOCK/NPAS2 regulatory complex, thereby shutting
down their own transcription. The PER and CRY heterodimers are progressively degraded,
allowing the circuit to start again. This negative feedback leads to a cycle in gene expression
that takes approximately 24 hours to complete (Figure 2) [43].
Figure 2. Schematic representation of the core circadian clock. (Adapted from Robinson and Reddy [52]. Copyright
©2014). BMAL1 and CLOCK transcription products translocate to the cytoplasm and dimerize. They then return to the
nucleus and bind to E-box regions and promote Period (PER) and Cryptochrome (CRY) transcription. PER and CRY
translocate to the cytoplasm, dimerize, and return to the nucleus and inhibit the binding of the CLOCK/BMAL com‐
plex. PER and CRY are subsequently degraded. REV-ERB inhibits the transcription of Bmal1, whereas ROR promotes
BMAL1 expression. The clock-controlled genes REV-ERBα (REV-ERB) and RORα (ROR) generate additional circadian
control by modulating the expression of BMAL1.
Post-transcriptional and post-translational modifications, such as phosphorylation,
acetylation, methylation, sumoylation, and ubiquitination, are crucial to the clock molecular
mechanism [44]. Post-translational modifications of the proteins of the circuit generate the
essential time delay that maintains the period of the cycle at approximately 24 hours.
Additional feedback pathways involving nuclear receptors, such as RORα (retinoid-related
orphan receptor alpha), REV-ERBα (NR1D1, nuclear receptor subfamily 1, group D, member
1), PPARγ (peroxisome proliferator–activated receptor gamma), and PGC-1α (peroxisome
proliferator–activated receptor gamma coactivator 1-alpha) provide further robustness to the
circuit [45, 46]. Additionally, these clock genes control numerous target genes (termed clock
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controlled genes, CCGs) and they regulate the circadian rhythms of various biochemical and
physiological processes [47].
4.2. Redox regulation of circadian rhythms
The possible relation between circadian rhythm and redox state has been long known but it
was unclear whether redox oscillations are a driver of the clock or a biomarker of cellular time.
The discovery that circadian redox oscillations appear to be conserved throughout evolution,
and that circadian oscillations in redox parameters persist in the absence of transcriptional
system, has consolidated the interplay between metabolic processes and the molecular clock
[48]. In mammals, nearly 10,000 genes are known to be under circadian control [49]. Several
studies have investigated circadian oscillations in gene expression in metabolic tissues,
including brown fat, liver, and skeletal muscle [50]. Certain metabolic enzymes are rhythmi‐
cally expressed in the liver, such as aconitase, aldolase 2, enolase 1, ketohexokinase, and
succinate dehydrogenase 1 [51]. Since numerous metabolic diseases appear to have a circadian-
related dysfunction, it follows that core cellular metabolism and the clock are intimately
connected [52].
The redox state of a cell has been shown to be an integral component in the regulation of the
molecular clock. DNA binding of NPAS2 and CLOCK is influenced by the redox state of
NAD(H) and NHAP(H). NADP inhibits NPAS2:BMAL1 binding to DNA, but, on the other
hand, DNA binding is promoted by NADPH. At a ratio of NADP:NADP(H) of over 75%
NPAS2:BMAL1 DNA binding increases, whereas below 75% binding decreases [53].
Peroxiredoxins (PRDXs) are a family of antioxidants that help to prevent cellular damage
resulting from the production of ROS and work by reducing H2O2 to water. Six PRDX isoforms
are known (PRDX 1–6), and they are found in different cellular localizations: isoforms 1, 2, 5,
and 6 in the cytosol, isoforms 3 and 5 in the mitochondria, isoform 5 in the peroxisome, and
isoform 4 in the endoplasmic reticulum [54, 55]. PRDXs could have one or two redox active
cysteine residues that bind H2O2 forming a sulfenic acid. In mammals, there are five two-
Cysperoxiredoxins (PRDX 1–5) and a single one-Cysperoxiredoxin (PRDX 6) [56]. In most
cases, a homodimer is formed by a resolving cysteine at the C terminus forming a disulphide
bond with the cysteine sulfenic acid. This bond can then be ‘resolved’ by thioredoxin, enabling
further catabolism of peroxide by PRDX [57].
The cycle of PRDX had been shown to follow a circadian rhythm, with two forms of PRDX6
oscillating in antiphase in the liver, emphasizing a role of post-translational modification in
circadian rhythmicity [51]. While the core clockwork use TTFLs, many works suggest the redox
state of PRDXs is driven by the metabolic state of the cell, but it is independent of transcription
[58]. However, the reciprocal influence between the TTFL and the PRDX-based metabolic clock
has not fully addressed yet.
4.3. Epigenetic regulation of circadian rhythms by miRNAs
Some miRNAs have regulatory functions contributing to the control over circadian protein
expression [59]. The influences of the circadian clock function on miRNA expression or vice
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versa have been well established. Experimental evidence suggests that up to 30% of core clock
genes are under the control of miRNA. Recently, miR-132 and miR-219 seem to be directly
involved in the clock system and regulate light response [60].
Other studies examine the role of extracellular miRNAs in the regulation of molecular
components and modulation of rhythmicity in peripheral cellular clocks. The studies revealed
that exposure to miR-142-3p– and miR-494–enriched conditioned medium increases intracel‐
lular expression of these miRNAs and results in functional effects in recipient cells [59].
4.4. Circadian rhythms and CRC
In carcinogenesis, the levels of expression of many proteins may be dependent directly or
indirectly on the circadian cycle. Investigations on the relation between the circadian clock and
DNA damage response have revealed that DNA damage checkpoints, nucleotide excision
repair, and apoptosis are appreciably influenced by the clock [61]. Changes in the circadian
rhythm of cell division are considered important component in neoplastic transformation. The
presence of DNA damage is usually associated with cell cycle arrest for attempted repairs or
induction of apoptosis. The mechanism of repair happens before the S-phase of the cell cycle,
and although there are post-replication mechanisms for induction of cell cycle arrest, the
G1/S checkpoint is usually the most stringent cell cycle checkpoint and this event will take
place at night for adjustment of the circadian rhythm [61]. On the other hand, disruptions of
the circadian rhythm genes are associated with increased susceptibility to cancers [62].
Some experimental studies have showed the role of the disruption of the molecular clock work
in colorectal carcinogenesis and CRC progression [63]. One example is seen in human cancer
cells lines when PER1 is overexpressed. In this experiment, it was observed a reduced colony
formation and clonogenic expansion, in sensitization to radiation-induced apoptosis, and in
altered expression of transcriptional target genes, such as c-MYC and p21 [64]. In contrast,
PER2-null mice showed an increase in hyperplasia and neoplasia in response to γ-radiation
[65]. In line with this work, restoring CLOCK expression in a human colon adenocarcinoma
cell line derived from a primary colon cancer, in response to ionizing radiation, conferred
protection against ultraviolet (UV)-induced apoptosis and decreased G2/M arrest [66].
On the other hand, one study that used CRC tumor tissue from patients demonstrated that
PER2 expression was higher in well-differentiated cancer cells when compared to poorly
differentiated ones. Associations of decreased PER2 levels with patient age, histological grade,
TNM (for tumors/nodes/metastases) stage, and expression of nuclear proliferation-related
antigen Ki67 were also observed [67]. In addition, down-regulation of PER3 associated with
various clinicopathological factors, including tumor location, differentiation, and stage, as well
as poorer survival was seen in CRC tissues, thus suggesting an important role in CRC
progression [68].
The efficacy of many drugs and the intensity of their effects depend on the time of day when
they are administered (chronochemotherapy), and they are therefore associated with the
circadian rhythm. The clock acts as a modulator of the pharmacokinetics and pharmacody‐
namics of chemotherapeutic drugs and of the activity of the DNA-repair enzymes that repair
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the DNA damage caused by anticancer drugs [61]. Some studies have demonstrated that
chronomodulated chemotherapy has better tolerability and antitumor activity compared with
conventional chemotherapy. A good example is the treatment of advanced stage CRC where
oxaliplatin is administered in the afternoon and 5-FU and leucovorin are delivered late at night
(chronoFLO4) [69]. Other authors have observed that 5-FU administration during the sleeping
time before radiotherapy could have an advantage as a chronotherapy and also as a radiosen‐
sitizer [70].
4.5. Regulation of stemness by the circadian machinery
Numerous studies are demonstrating the importance of coherent circadian oscillations for a
variety of homeostatic functions of tissues. One example is the timed activation and differen‐
tiation of stem and progenitor cells, and how perturbation of this temporal coordination leads
to pathologies, including obesity and neurological diseases, aging, and cancer [71].
Like normal cells, cancer cells contain molecular clocks that generate circadian rhythms in gene
expression and metabolic activity [72]. The circadian rhythms not only regulate the cell cycle
in normal differentiated cells but there could also be a functional relation between circadian
rhythm gene expression and the intrinsic control of the proliferation of CSCs and progenitor
cells in different tissues [73]. In rodents and humans, all the hematopoietic stem and progenitor
cells exhibit a predictable circadian variation [74, 75]. Some authors have shown that there is
an increase in circadian rhythm gene expression of highly differentiated stem cell cultures. In
both cancer and normal cells, a rhythmic nuclear translocation of PER2 and other critical clock
proteins is an essential part of a clock timing mechanism based on transcriptional–translational
feedback loops and rhythmic chromatin modification [73, 76].
The malignant phenotype depends not only on the characteristics of the cancer cell itself but
also on the tumor microenvironment. CSCs have to survive for a long time in the body to
generate the highly tumorigenic cells responsible for the clinical manifestations of cancer.
During this period, the niche helps to shelter CSCs from different types of insults, such as the
immune response and chemotherapy-induced genotoxic stress [77, 78]. This suggests that the
niche may also play a protective role for CSCs, thus increasing the risk of cancer. In fact, BMAL1
suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-Matrix
metalloproteinase-2 (MMP-2) signaling pathway [79]. Other authors have reported circadian
oscillations in the levels of MMP-9 [80].
5. SIRT1 and the circadian regulation of CSCs by miRNAs
The silent information regulator (SIRT) 2 family of proteins, known as sirtuins, is a class III of
histone deacetylases or NAD+−dependent deacetylases and is conserved from bacteria to
humans. The requirement for NAD+ links the activity of sirtuins directly to the metabolic state
of the cell, since the deacetylase activity of these proteins is controlled by the cellular NAD+/
NADH ratio. There are seven sirtuins (SIRT1–7) in mammals. They have different specific
substrates and biological functions and are found in various cell compartments [81].
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The role of sirtuin activation in mammals is to regulate the progression of aging and age-
associated disorders, including neurodegeneration, diabetes, cardiovascular diseases, and
many types of cancer [82]. The best characterized and well-studied among the human sirtuins
is SIRT1. It can be found in the nucleus and in the cytoplasm of the cells [83].
5.1. Sirt1 in cancer biology
SIRT1 is overexpressed in some types of human cancer tissues, such as ovary, liver, breast,
stomach, pancreas and prostate, and down expressed in skin cancer. In CRC, SIRT1 is also
overexpressed. However, other investigations have revealed pronounced SIRT1 expression in
both normal colon and tumor tissues, although its expression is substantially reduced in higher
grade CRC tumors [84].
SIRT1 has a dual role in tumorigenesis, where it can function as either a tumor promoter or a
tumor suppressor. Its function in malignancy varies with concentration, cellular location,
temporal and spatial distribution, and regulation by upstream and downstream factors [85].
The initial connection of sirtuins to cancer was made when SIRT1 was found to deacetylate
and repress the activity of the tumor suppressor p53 [86, 87]. SIRT1-mediated deacetylation
suppresses the functions of other tumor suppressors, including p73, hypermethylated in
cancer 1 (HIC1), E2F transcription factor 1(E2F1, also known as retinoblastoma-associated
protein 1), retinoblastoma protein (Rb), and phosphatase and tensin homologue deleted in
chromosome 10 (PTEN), thus suggesting that SIRT1 acts as a promoter in tumor development
and progression [88–93]. Other reports showed SIRT1 as a downstream of the oncoprotein
BCR-ABL tyrosine kinase (Abelson murine leukemia viral oncogene homolog 1), implicated
in the development of chronic myelogenous leukemia (CML)-like myeloproliferative disease
[94].
Autophagy is a self-degradative process that plays a role by eliminating damaged organelles
and misfolded or aggregated proteins through the lysosomal degradation pathway. Autoph‐
agy initially serves as a protective process to prevent cancer initiation; however, after neo‐
plastic transformation, it can promote tumor cell survival and maintenance [95]. Autophagy
can also affect chemotherapeutic and immunotherapeutic response in cancer cells making it
an attractive target for development of anticancer drugs [96, 97]. SIRT1 forms a molecular
complex with the genes related to autophagy and autophagosome formation, Atg5, Atg7, and
Atg8. Loss of SIRT1 activity results in the acetylation of those factors thus leading to defects
in the process of autophagy [98].
Consistent with a tumor-suppressor role, SIRT1 deacetylates and decreases the stability of the
oncogene c-MYC [99]. In addition, the activity of SIRT1 can be increased by some tumor-
suppressors, for example BRCA1 (breast cancer 1) [99]. SIRT1 exerts anticarcinogenic effects
through multiple mechanisms [83]. SIRT1 can counteract various genotoxic insults, including
oxidative DNA damage, thereby blocking initiation of carcinogenesis. SIRT1 deacetylates and
inhibits proapoptotic p53 and PARP-1 (poly (ADP-ribose) polymerase 1) under stressful
conditions, conferring cell survival [86, 100]. SIRT1 is also required for DNA repair processes
to maintain genomic stability [101, 102].
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SIRT1 inhibits the mediators involved in aberrantly amplified proinflammatory signaling
during promotion and progression of carcinogenesis [103–105]. The anti-inflammatory effect
of SIRT1 might be achieved by inhibition of several transcription factors related to inflamma‐
tion, nuclear factor κB (NF-κB), signal transducer and activator of transcription 3 (STAT3), and
the c-Jun and fos elements of transcription factor activator protein 1 (AP-1) [106–108]. Mainly
through NF-κB and AP-1 pathways, SIRT1 was engaged in macrophage and T-cell activation
[105, 109]. SIRT1 also regulates the differentiation and function of iTreg (induced Treg helper
cells) [110]. Interestingly, SIRT1 translates metabolic cues during regulation of the immune
responses, which would bring new insights into both pathogenesis and potential therapeutic
strategies of a variety of immune-related diseases, such as cancer [111].
5.2. SIRT1 and stem cells
SIRT1 is considered an old multifaceted enzyme with an important role in the maintenance of
pluripotency in various types of stem cells. Most of the in vivo data suggest that Sirt1 acts in
early development as a modulatory molecule on basic developmental processes [112]. In
cancer, SIRT1 has been implicated in the regulation of CSCs survival and differentiation. SIRT1
has been found to regulate the growth and survival of leukemia stem cells (LSCs) and confer
resistance against chemotherapy [113], stimulate endometrial cell tumor growth through
lipogenesis [114], maintain neural stem cells and promote oncogenic transformation [115], and
foster hepatocellular carcinoma [116]. As a result, SIRT1 and agents that modulate SIRT1
activity may represent new therapeutic strategies against tumorigenesis.
One of the more intriguing hypotheses about aging and age-related disease is that age-
associated phenotypic alterations derive from the inability of resident stem cells to maintain
tissue structure and function [117]. This suggests that the aging process could arise from loss
or malfunction of self-renewal and/or differentiation potential in adult stem cell populations.
SIRT1 has a positive role in stemness by aiding in the silencing of differentiation genes, which
suggests new potential explanations of its ability to extend lifespan and to avoid cell and
organism senescence [112, 118].
5.3. SIRT1 and miRNAs
Expression of SIRT1 is controlled at multiple levels by transcriptional, post-transcriptional,
and post-translational mechanisms under physiological and pathological conditions [119].
Deacetylation activity of SIRT1 can be modulated by multiple regulators. AROS (Active
regulator of SIRT1) and DBC1 (deleted in breast cancer 1) are positive and negative regulators
of SIRT1, respectively [120, 121].
Emerging evidence indicates that miRNAs are important regulators of SIRT1 expression and
activity [119]. In cancer, SIRT1 mediates miR-34a activation of apoptosis by regulating p53
activity. In addition, p53 induces expression of miR-34a which suppresses SIRT1, increasing
p53 activity [122]. In CRC, dysregulation of microRNA-34a expression causes drug-resistance
to 5-FU in human colon cancer cells through the downregulation of Sirt1 and E2F3 [123, 124].
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miRNAs play an important role in proper function and differentiation of human and mouse
stem cells. Recently, it has been demonstrated that miR-34a is required for proper differentia‐
tion of mouse embryonic stem cells, mouse neural stem cell, and mouse embryonic fibroblasts
and that it function in part by targeting SIRT1 and modulating p53 activity [125–127]. Also,
the miR-29b-Sirt1 axis regulates self-renewal of mouse embryonic stem cells in response to
reactive oxygen species [128]. miR-34a is also a critical regulator of cancer progression by the
regulation of CSC characteristics, through SIRT1 as a mediator [129–133], and mainly, through
up-regulation of p53/p21 [131].
5.4. SIRT1 as regulator of circadian rhythms
Two independent studies identified SIRT1 as a critical modulator of the circadian clock
machinery. Asher et al. [134] observed oscillations in SIRT1 protein levels, and Nakahata et al.
[135] demonstrated that SIRT1 activity, and not its protein levels, oscillates in a circadian
manner. SIRT1 modulates circadian rhythms by deacetylating histone H3 Lys9 and Lys14 at
promoters of rhythmic genes, BMAL1 and PER2. The CLOCK-BMAL1 complex interacts with
SIRT1 and recruits it to the promoters of rhythmic genes. While BMAL1 acetylation acts as a
signal for CRY recruitment, PER2 acetylation enhances its stability [134]. These findings led to
the concept that SIRT1 operates as a rheostat of the circadian machinery, modulating the
amplitude of CLOCK-mediated acetylation and consequent transcription cycles [135].
Circadian oscillation of SIRT1 activity suggested that cellular NAD+ levels may also oscillate.
In fact, circadian clock controls the expression of NAMPT (nicotinamide phosphoribosyl‐
transferase), a key rate-limiting enzyme in the salvage pathway of NAD+ biosynthesis. The
oscillatory expression of NAMPT is abolished in Clock/Clock mice, which results in drastically
reduced levels of NAD+. These results imply the existence of an enzymatic/transcriptional
feedback loop, wherein SIRT1 regulates the levels of its own cofactor [135]. These results also
connect the circadian machinery to cell metabolism [134].
SIRT1 either directly or indirectly can influence the redox property of the cell [136]. In addition
to reduce cellular oxidative stress burden, SIRT1 is also regulated by oxidative stress [137].
Since redox homeostasis influence circadian machinery, SIR1 could regulate circadian genes
trough redox status of the cell. A recent report suggests that PRDX2 regulates the TTFL
oscillation by decreasing the nuclear redox levels and increasing SIRT1 enzymatic activity,
although neither a direct interaction between PRX and SIRT1 nor a modulation of SIRT1
intracellular levels by PRX was found [138].
5.5. SIRT1 regulators as new tools for cancer treatment
Recently, multiple research groups have pursued the identification and development of small
molecule compounds that modulate sirtuins SIRT1 regulators as new tools for cancer treatment
[139]. To date, SIRT1 inhibitors and activators have been described with different effects on
cancer [140].
SIRT inhibitors require combined targeting of both SIRT1 and SIRT2 to induce p53 acetylation
and cell death, like sirtinol and salermide [139]. Trichostatin A (TSA) and sirtinol induce
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p38MAPK- and AMPK-mediated downregulation of survivin and its functional correlation
with decreased colon cancer cell viability in vitro [141]. Other salermide-related sirtuin
inhibitors show antiproliferative effects in colon cancer cells in vitro, including CSCs [142].
Vorinostat activates p53, but does not require p53 for inducing its anticancer action in CRC
[143]. The SIRT1 selective inhibitor Amurensin G may be effective in eliminating colon CSCs
and may be applicable to potentiate the sensitivity of colon CSCs to TNF-related apoptosis-
inducing ligand (TRAIL) [144].
Studies have shown that the sirtuin activator resveratrol, a polyphenol found in wines has
chemopreventive activity against various cancers. In CRC, resveratrol induce apoptosis and
suppressed the PI3K/Akt signaling pathway. The combination treatment with resveratrol and
5-FU induced a synergistic enhancement of growth inhibition and apoptosis in colon cancer
DLD-1 cells. Interestingly, resveratrol increased the intracellular expression level of miR-34a,
which down-regulated the target gene E2F3 and its downstream Sirt1, resulting in growth
inhibition [145].
Melatonin is the main secretory product of the pineal gland and plays important roles in several
biological functions, including circadian rhythms, sleep, mood, reproductive physiology, and
aging diseases [146]. Numerous studies based on animal and clinical data have provided
evidence that melatonin reduces the incidence of experimentally induced cancers and may
significantly inhibit the growth of some human tumors [147]. Recently, melatonin was
confirmed as a novel inhibitor of SIRT1. Melatonin inhibits prostate cancer and osteosarcoma
cell growth through SIRT1 inhibition [148, 149]. Interestingly, it was recently reported that
melatonin decreases CSCs and dysplastic injuries in colon tissue [150].
6. Concluding remarks
SIRT1 expression correlated with depth of invasion, lymph node metastasis, and TNM stage
in CRC. Simultaneously, SIRT1 overexpression predicted a poor overall survival in CRC
patients, and SIRT1 is a candidate negative prognostic biomarker for CRC patients [151]. SIRT1
has also been implicated in chemoresistance in CRC patients with [152] or without metastasis
[124]. Further investigations aimed at targeting SIRT1 alone or in combination with chemo‐
therapy deserve further attention and may ultimately increase response rates in the treatment
of CRC. In this sense, melatonin can significantly amplify the cytostatic and the cytotoxic effects
triggered by other compounds or conventional drugs. We are far from having a satisfactory
understanding about how and when melatonin exerts its beneficial effects. Melatonin in the
nanomolar range induces down-regulation of SIRT1. This finding is of great relevance because
there is intense research ongoing to identify nontoxic feasible inhibitors of SIRT1. Melatonin
should be evaluated for the management of those cancers where this protein is overexpressed
and is functional.
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